Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.
| Revenue (Most Recent Fiscal Year) | $203.07M |
| Net Income (Most Recent Fiscal Year) | $-54.84M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.54 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -21.41% |
| Net Margin (Trailing 12 Months) | -20.25% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -12.07% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.72 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.17 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 0.84 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.22 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.30 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 156.38M |
| Free Float | 146.27M |
| Market Capitalization | $788.18M |
| Average Volume (Last 20 Days) | 2.03M |
| Beta (Past 60 Months) | 1.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.47% |
| Percentage Held By Institutions (Latest 13F Reports) | 42.75% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |